Asunto(s)
Enfermedades de la Piel , Humanos , Parestesia/terapia , Prurito/etiología , Prurito/terapiaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Persona de Mediana Edad , Hidradenitis Supurativa/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Resultado del Tratamiento , Índice de Severidad de la Enfermedad , Uso Fuera de lo Indicado , Factores de TiempoRESUMEN
BACKGROUND: T-helper (Th)-17 lymphocytes and neutrophils are the main sources of the proinflammatory cytokines involved in the pathogenesis of hidradenitis suppurativa (HS). OBJECTIVES: This study aims to evaluate the improvement of the inflammatory serum markers (ISM) levels in patients with moderate-to-severe HS who receive adalimumab. METHODS: Nineteen moderate-to-severe HS patients were prospectively recruited. Each of the patients received 40â¯mg of adalimumab weekly. The ISM levels and modified Hidradenitis Suppurativa Score (mHSS) scores were assessed at baseline and at week 36. Nineteen healthy volunteers (HC) constituted the control group. RESULTS: Before adalimumab treatment, the HS patients showed significantly increased levels of interleukin (IL)-6, IL-8, IL-10, IL-17A, soluble TNF receptor II (sTNF-RII), and C-reactive protein (CRP) as well as an increased erythrocyte sedimentation rate (ESR) (all Pâ¯<â¯.01). At week 36, the circulating levels of IL-1ß, IL-6, IL-8, IL-10, IL-17A, soluble TNF receptor I (sTNF-RI), sTNF-RII, and CRP, as well as the ESR (all Pâ¯<â¯.05), decreased significantly in the HS patients who received adalimumab. The decrease in levels of IL-6 (râ¯=â¯0.65, Pâ¯=â¯.003), IL-8 (râ¯=â¯0.52, Pâ¯=â¯.024), sTNF-RI (râ¯=â¯0.55, Pâ¯=â¯.015), and CRP (râ¯=â¯0.47, Pâ¯<â¯.040) and the ESR (râ¯=â¯0.60, Pâ¯<â¯.006) were significantly well correlated with clinical improvements according to the mHSS. CONCLUSIONS: Adalimumab improves the ISM-based systemic inflammatory burden in patients with moderate-to-severe HS. IL-6, IL-8, sTNF-RI and CRP and the ESR may serve as novel biomarkers for a therapeutic response.